We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener

Session Item

Clinical track: Lower GI (colon, rectum, anus)
9306
Poster
Clinical
00:00 - 00:00
THE ENERGY METABOLISM CHANGES IN RECTAL CANCER PATIENTS AFTER NEOADJUVANT RADIOCHEMOTHERAPY
PO-1103

Abstract

THE ENERGY METABOLISM CHANGES IN RECTAL CANCER PATIENTS AFTER NEOADJUVANT RADIOCHEMOTHERAPY
Authors: ACOSTA|, Johana(1)*[johanacacostaa@gmail.com];Rodríguez|, Elisabet (1,2);Moreno|, Azafne (2);Gomez |, Junior(1);Torres|, Laura(1);López|, Yolanada(1);Trilla|, Jordi(1);Baiges|, Gerard(2);Hernández|, Anna(2);Joven|, Jorge(2);Camps|, Jordi(2);Arenas|, Meritxel(1,2);
(1)Hospital Universitari Sant Joan de Reus, Department of Radiation Oncology, Reus, Spain;(2)Institut d’Investigació Sanitària Pere Virgili- Universitat Rovira i Virgili, Unitat de Recerca Biomèdica, Reus, Spain;
Show Affiliations
Purpose or Objective

The aim of this study was to investigate changes in energy metabolism associated with neoadjuvant radiochemotherapy (NRCT) in patients with locally advanced rectal cancer (RC).

Material and Methods

Thirty-two patients (men, n= 22; women, n= 10) with locally advanced RC had been included in the study between 2014 and 2018. Blood samples were collected before and one month after NRCT. A Gas Chromatography/Mass Spectrometry sequence was used to determine plasma concentration of energy balance-associated metabolites. Metabolites involved in the glycolysis, citric acid cycle and amino acid metabolism were analysed. All statistical calculations and graph representations were performed with the statistical package for social sciences (SPSS 22.0) and GraphPad Prism 6.01 (GraphPad Software, San Diego, CA, USA).

Results

Most of the metabolites involved in glycolysis, citric acid cycle and amino acid metabolism had major variations in RC patients compared to healthy individuals. Concretely, plasma glucose, pyruvate and glutamine concentrations were significantly higher in patients with RC. On the other hand, lactate, alanine, valine, leucine, fumarate, malate, αketoglutarate, glutamate and aconitate concentrations were significantly lower. NRCT significantly modified lactate, fumarate and glutamine concentrations, which tended to normal values. Hydroxybutyrate was the metabolite with the best discriminant capacity between patients before and after NRCT. In addition, the metabolic profile before NRCT was different in patients with acute toxicity and Dworak tumour regression grade 2 and 4 (Figure 1 and Table 1).


Conclusion

Results obtained in this study show clear alterations in glycolysis, citric acid cycle and amino acid metabolism in RC patients. Significant differences between the control and cancer groups were observed in the plasma concentrations of many metabolites. Lactate, fumarate and glutamine values returned to similar levels to those of the control group after NRCT, meaning that the NRCT is also able to modify the metabolic profile of RC patients.